Top of page Skip navigation

    Early Bird Rates available - register today and save


    Exhibitor packages available - reserve your space today

We are delighted that the following organisations are exhibiting at this year's UK Bioscience Forum



Amici Procurement Solutions provides a purchasing service to the Biotech and Pharma Industry – from start up labs to established multinationals and Major Pharma. The aim is to deliver cost savings to the client, and probably more importantly to ensure clients have the right tools and support to prosper without detracting from their scientific objectives in this time pressured market.

Amici has an enthusiastic team of scientific purchasing professionals who specialise in every aspect of the purchasing service including sourcing, cost saving programs, management reporting of procurement information, LEANing the PO to Pay Process in conjunction with the clients finance, through to managing every aspect of a transaction to get the products and services delivered on time in full at the right quality and price. The Amici solution is underpinned by a cutting edge scientific e-procurement platform which has evolved over the past 7 years to specifically support the needs of this sector.




HMRC’s Incentives and Reliefs teams are specialists in R&D tax credits for both SMEs and large companies and are also now set up to give advice on the new Patent Box legislation. If you have any queries relating to these areas or would like any further information, please come and see us.



 Horizon Discovery is a revenue-generating life science group supplying research tools to organizations engaged in translational genomics research and the development of personalized medicines. Horizon has a diverse and international customer base of over 1,200 organizations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers over 20,000 catalogue products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

In addition, Horizon provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.


JDRF’s vision is a world without type 1 diabetes, an indiscriminate and devastating life-long condition most commonly diagnosed in childhood. They develop cutting-edge advances in treating, preventing and curing type 1, as well as advancing technologies to improve the long-term health and life expectancy of people with the condition. Globally, they have been at the forefront of all major breakthroughs in type 1 research.

JDRF also provide information and support to families living with the condition, and give a voice to people with type 1 by campaigning for greater research funding and for better access to life-changing treatments and technologies.



Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical applications. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Our 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer.



Alderley Park has a strong history of drug discovery and development and is set in 400 acres of Cheshire countryside.
A dedicated Life Science Enterprise Zone, it offers 1m sq ft of premier scientific laboratory space and over 400,000 sq ft of office space all accompanied by great retail, leisure and a vibrant social events programme. 

Alderley Park is home to over 150 biotech and life science companies and a number of key assets including, the Medicines Discovery Catapult, the translational centre for AMR, a Waters open access lab. It’s community of 3000 people and growing fast makes it a perfect home for your business. The Park is well connected
and easily accessible – it’s only 10 miles to Manchester airport, 18 miles to Manchester city centre and great rail links make London less than 2hrs away.




Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, plasma-derived proteins, vaccines and classic pharmaceuticals.  Pall’s leading edge filtration, single-use systems, separation, purification and analytical technologies, as well as technical services in validation, assays and process optimization applicable to laboratory and pilot-scale development, play an essential role in the industry’s ability to manufacture these products.  

As an established provider of analytical and purification technologies, Pall supports faster development of new drugs and vaccines around the world.




Public Health England (PHE) is a new Executive Agency of the UK Department of Health that is responsible for protecting and improving the nation’s health and wellbeing and reducing inequalities.  With ~6000 staff and £1 billion operational budget, we provide a nationwide, integrated public health service supporting people to make healthier choices and providing expertise, information and intelligence.  Our translational research, development and testing programmes focus on diagnostics, vaccines and other interventions across healthcare and public health.

Translating research into production
Porton Biopharma Limited was established earlier this year to commercialise the pharmaceutical development and manufacturing capabilities at the Porton Down site in Wiltshire that were previously within Public Health England.

We develop new vaccines, therapeutic proteins and enzyme products, and also manufacture our own licensed biopharmaceutical products, Erwinase® and Anthrax Vaccine (alum precipitated sterile filtrate). With specialist expertise in the development of both manufacturing and analytical processes for use with biological pharmaceutical products. As well as undertaking contract manufacture at all stages of the product development/commercialisation lifecycle, we can help you successfully develop your product. 

Potter Clarkson


Potter Clarkson LLP is an award winning firm top tier of European patent and trade mark attorneys. The firm advises clients worldwide on patents, trademarks, designs and associated aspects of intellectual property.  The 145 strong team includes over 55 patent and trade mark professionals working together at a single site in Nottingham.  Their technical qualifications and experience are outstanding.  Specialist sectors include: Biotechnology and Pharmaceuticals; Chemistry; Designs and Engineering; Electronics and Computing; and Energy and Clean Technologies.


Stratagem Intellectual Property Management Ltd is a full-service, Cambridge UK-based, out sourced intellectual organisation and management company with global reach.

Stratagem IPM Ltd fills a developing need within industry for the provision of strategic advice and intellectual property management for life science, medtech, cleantech and high technology companies.  Stratagem’s qualified patent and trade mark attorneys use a commercial perspective and hands on management approach to enhance the value of IP assets.